Prostatype Genomics Total Risk Alpha
| PROGEN Stock | | | SEK 0.91 -0.13 -12.50% |
The Total Risk Alpha reading for Prostatype Genomics AB is computed from historical trading observations. Each data point is derived from standardized price and volume feeds. Indicator reliability depends on the continuity of available trading data. Prostatype Genomics has a market cap of 42.29 M, operating margin of -23.61%, ROE of -70.24%. Review
Your Equity Center for a broader allocation view. Portfolio composition is shown for contextual purposes. A position in Prostatype Genomics AB appears within the mix. The allocation reflects this within the position set. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in unemployment.
Prostatype Genomics AB has current Total Risk Alpha of 3.69. The total risk alpha measures the performance of an asset by comparing its returns with those of a selected benchmark portfolio.
Total Risk Alpha | = | RFR + (ER[b] - ER[a]) | x | STD[a] / STD[b] |
| = | 3.69 | |
| ER[a] | = | Expected return on investing in Prostatype Genomics |
| ER[b] | = | Expected return on market index or selected benchmark |
| STD[a] | = | Standard Deviation of returns on Prostatype Genomics |
| STD[b] | = | Standard Deviation of selected market or benchmark |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
Total Risk Alpha Peers Comparison
Total Risk Alpha Relative To Other Indicators
Prostatype Genomics AB is rated
second in total risk alpha among leading competitors. It is currently under evaluation in maximum drawdown among leading competitors reporting about
21.52 of Maximum Drawdown per Total Risk Alpha. At
21.52 , Prostatype Genomics AB's Maximum Drawdown-to-Total Risk Alpha multiple reflects the spread between these metrics
The benchmark portfolio represents the market risk matched to the total risk of the stock ETF or fund.
Compare Prostatype Genomics to Peers
Other Technical Indicators